AI Video Ads for Collagen Supplements: The Rejected-Claim Category

Collagen has the dubious distinction of being the most-rejected ingredient category in the EU authorised health claims register. Every collagen-specific application for skin and joint endpoints has been turned down. The functional benefit collagen brands actually want to claim, that ingesting collagen peptides supports skin or joint structure, has no authorised wording. AI video tools default to that exact claim, which is why collagen sits alongside nootropics as one of the two supplement categories with the highest ASA-ruling rate.

The brands operating at scale solved the problem the same way the supplement industry solved it on the labels: the cofactor pivot. Vitamin C contributes to normal collagen formation. Biotin contributes to the maintenance of normal skin. Zinc contributes to the maintenance of normal hair, skin, and nails. These are authorised. The collagen itself is the format; the cofactor is the claim.

What follows is the briefing pattern that produces collagen ads the ASA accepts.

Why collagen is the most rejected claims category

The EU health claims regulation requires positive scientific opinion from EFSA for any health claim attached to a food. Collagen-specific applications have been submitted for skin elasticity, skin moisture, joint health, joint mobility, and bone density. Every one has been rejected on insufficient evidence. The EU register of nutrition and health claims, retained in UK law, lists each application individually.

The ASA enforces this consistently. "Plumps skin", "smooths wrinkles", "rebuilds joints", "fixes hair thinning" are routine ASA-rulings against collagen brands. Several DTC collagen brands have cycled through three or four ad accounts within a single calendar year. The pattern is familiar to anyone who has run paid for a collagen brand: variant performance climbs, complaint comes in, account dies, variant is recycled under a new domain, the cycle repeats.

The US position is slightly looser. The FTC accepts structure-function claims for collagen peptides where evidence exists, but the bar is meaningfully higher than for vitamins. Branded ingredient peptides (Verisol, Peptan) carry their own clinical trial data, which gives access to structure-function wording the generic peptide products cannot use. The trial data does not transfer to UK authorisation; it does not move EFSA's position.

The cofactor pivot

Most successful collagen DTC brands sell a product that contains collagen peptides plus vitamin C plus biotin, sometimes with zinc and hyaluronic acid added. The formulation choice is not coincidental. It is the only legal route to skin claims in the UK.

Vitamin C contributes to "normal collagen formation for the normal function of skin". Biotin contributes to "the maintenance of normal skin". Zinc contributes to "the maintenance of normal hair, skin, and nails". A product that includes a meaningful dose of any of these can use the authorised wording in advertising. The collagen content is positioned as the format and protein source; the cofactor carries the claim.

The script structure that the ASA accepts looks like this: "I take a collagen peptide blend with vitamin C, which supports normal collagen formation for the function of my skin." The same script without the vitamin C reference, "I take a collagen peptide blend that supports my skin," is non-compliant.

This is where AI video tools default off-brief. They will generate the second version on the first attempt, because the training data is full of the second version.

Where AI tools default to over-claim

Briefed with "30-something woman drinks collagen powder, says it improved her skin", the model generates the requested scene with a script that promises improvement, transformation, or visible results within a stated timeframe. None of those framings is on the authorised register for collagen, vitamin C, biotin, or zinc.

The negative-constraint instruction is the same shape as for other supplement categories: "Do not claim collagen improves skin, plumps skin, smooths wrinkles, or reduces signs of ageing. Do not promise visible results. Use only the authorised wording: vitamin C contributes to normal collagen formation for the normal function of skin." With that constraint, model output enters the envelope.

The pattern echoes the skincare-side compliance discipline documented in AI before and after videos for skincare ASA compliant, where the visible-result claim is the trigger.

Three prompt patterns that produce compliant output

These are simplified working briefs, not legal advice.

Pattern 1, morning ritual, vitamin C cofactor framing

Late-30s woman in a sunlit kitchen, morning, dressing gown, mug of coffee on the counter. Adds a scoop of collagen peptide blend with vitamin C to her drink. Talks about why the vitamin C content matters: it contributes to normal collagen formation for the function of skin, using authorised wording. Mentions she has used the product for four months as part of a broader skincare and lifestyle routine. Avoids any claim about visible results, plumping, or anti-ageing. Tone is reflective.

Pattern 2, post-workout, joint and skin angle

Early-40s active woman in workout kit, post-training, drinking a collagen and vitamin C blend. Talks about taking it as part of her recovery routine. References specifically that the formulation includes vitamin C contributing to normal collagen formation for the normal function of cartilage. Does not claim joint healing, joint repair, or pain reduction. Closes with a comment about consistency in training and supplementation.

Pattern 3, founder framing, formulation rationale

Brand founder in a clean studio setting, mid-40s. Explains why the product was formulated to include vitamin C and biotin alongside the collagen peptide blend. Names each authorised claim and the dose at which it applies. Tone is technical and slightly dry. Does not promise outcomes. Closes with a comment about why combination formulations reflect the regulatory environment more honestly than collagen-only products.

Cost framing for collagen DTC

Collagen has higher AOV than most supplement categories, with subscription LTV that compensates for the AI ad-cost economics being similar to the rest of the supplement segment. The 12 to 25 monthly variant cycle costs £4,000 to £20,000 with traditional UGC creators in the wellness category, versus £50 to £200 monthly through a vertical-aware AI platform.

The cost differential is consistent with Cost per AI video by model in 2026. The category-specific consideration: collagen brands with larger budgets often allocate the saved spend toward branded-ingredient licensing (Verisol, Peptan), which improves the substantiation position rather than the ad volume.

Cinematography notes for the category

Collagen ads default to morning routine, post-workout recovery, and founder-led formulation explainer. The morning routine is the highest-volume placement, and the visual register is well-supported by AI models. Soft natural light, kitchen interior, lived-in styling. Veo 3.1 and Sora 2 Pro produce strong output here; Kling 3.0 produces acceptable output with slightly stiffer talent expression.

The before/after visual is the placement to avoid. AI generation of skin transformation is both visually unreliable and definitionally non-compliant. The category lives or dies by the cofactor narrative, not by visual outcome demonstration.

FAQ

Can a UK collagen brand claim any direct skin benefit from collagen?

No. EFSA has rejected all collagen-specific skin claims. Brands have to attach the skin claim to vitamin C, biotin, or zinc within the formulation, using the authorised wording for those ingredients.

What about US claims for the same product?

The FTC accepts structure-function claims with substantiation. Branded ingredient peptides with their own clinical evidence can support structure-function language. Generic collagen peptide products without specific evidence are limited to the same cofactor approach the UK requires.

Does the disclosure of AI generation matter more in this category?

Yes, in practice. The before/after register is the archetype of consumer mistrust in cosmetic and supplement advertising; AI-generated testimonials in this category sit at the intersection of two concerns. Disclosure as a corner watermark or in ad copy is the safer position.

Are branded peptides (Verisol, Peptan) treated differently?

Yes, in marketing latitude rather than UK claim wording. Branded peptides give brands access to structure-function language in the US and slightly stronger substantiation positions in the UK. The claim wording itself is still constrained to the authorised register; the substantiation is what differs.

How does collagen compare to vitamin compliance broadly?

Vitamins have a wide authorised-claims register and well-mapped advertising patterns. Collagen has none of the former and inherits the latter only through cofactor formulation. The vitamin equivalent is covered in AI video ads for vitamin brands.

For the cross-vertical FTC framework that collagen brands operate under in the US, see FTC compliance for supplement ads in 2026.

---

100 free credits to test how Tonic generates collagen briefs that survive ASA review: tonicstudio.ai/signup?promo=UGC100.